The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The facility is over 79,000 square feet and is equipped with packaging lines
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The companies will leverage their respective proprietary technology platforms
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
